Biomedical Engineering Reference
In-Depth Information
Hepatology Available at http://www.ncbi.nlm.nih.gov/
pubmed/21425312. Retrieved 2011 May 27.
31. Heinemann L. (2011) New ways of insulin delivery. Int. J.
Clin. Pract. Suppl. (170), 31-46.
32. Nelson HS, Busse WW, Sanger M, Cutler G, Ellwanger C,
Chipman JJ. (2009) Short-term safety of somatropin inhalation
powder in adults with mild to moderate asthma. Allergy
Asthma Proc. 30(3), 325-332.
33. Widera A, Kim K-JJ, Crandall ED, Shen W-C. (2003) Trans-
cytosis of GCSF-transferrin across rat alveolar epithelial cell
monolayers. Pharm. Res. 20(8), 1231-1238.
34. Bitonti AJ, Dumont JA, Low SC, Peters RT, Kropp KE,
Palombella VJ, et al. (2004) Pulmonary delivery of an eryth-
ropoietin Fc fusion protein in non-human primates through an
immunoglobulin transport pathway. Proc. Natl. Acad. Sci. USA
101(26), 9763-9768.
35. Dumont JA, Bitonti AJ, Clark D, Evans S, Pickford M, New-
man SP. (2005) Delivery of an erythropoietin-Fc fusion protein
by inhalation in humans through an immunoglobulin transport
pathway. J. Aerosol Med. 18(3), 294-303.
36. Vallee S, Rakhe S, Reidy T, Walker S, Lu Q, Sakorafas P, et al.
(2012) Pulmonary administration of interferon Beta-1a-fc
fusion protein in non-human primates using an immuno-
globulin transport pathway. J. Interferon Cytokine Res. 32
(4), 178-184.
37. Dumont JA, Low SC, Peters RT, Bitonti AJ. (2006) Monomeric
Fc fusions: impact on pharmacokinetic and biological activity
of protein therapeutics. BioDrugs 20(3), 151-160.
38. Kim K-J, Malik AB. (2003) Protein transport across the lung
epithelial barrier. Am. J. Physiol. Lung Cell Mol. Physiol. 284
(2), L247-259.
39. Ferkol T, Cohn LA, Phillips TE, Smith A, Davis PB. (2003)
Targeted delivery of antiprotease to the epithelial surface of
human tracheal xenografts. Am. J. Respir. Crit. Care Med. 167
(10), 1374-1379.
40. Malakhov MP, Aschenbrenner LM, Smee DF, Wandersee MK,
Sidwell RW, Gubareva LV, et al. (2006) Sialidase fusion
protein as a novel broad-spectrum inhibitor of influenza virus
infection. Antimicrob. Agents Chemother. 50(4), 1470-1479.
41. Hedlund M, Aschenbrenner LM, Jensen K, Larson JL, Fang F.
(2010) Sialidase-based anti-influenza virus therapy protects
against secondary pneumococcal infection. J. Infect. Dis 201
(7), 1007-1015.
42. Larson JL, Kang S-K, Choi BI, Hedlund M, Aschenbrenner
LM, Cecil B, et al. (2011) A safety evaluation of DAS181,
a sialidase fusion protein, in rodents. Toxicol. Sci. 122(2),
567-578.
43. YadavMC, Lemire I, Leonard P, Boileau G, Blond L, Beliveau
M, et al. (2011) Dose response of bone-targeted enzyme
replacement
bone: pharmacokinetic and pharmacological properties of
acidic oligopeptide-tagged drugs. Curr. Drug Discov. Technol.
5(1), 39-48.
46. Shi B, Yu A, Liu Y, Li J, Jin J, Dong C, et al. (2007) Locally
activity-released bifunctional fusion protein enhances antith-
rombosis and alleviates bleeding risk. J. Thromb. Thromboly-
sis 24(3), 283-292.
47. Wang X, Zhang G, Wang L, Zhang Q, Qin Y, Wu C, et al.
(2009) A fusion protein with improved thrombolytic effect and
low bleeding risk. Thromb. Haemost. 102(6), 1194-1203.
48. Cizeau J, Torres MGP, Cowling SG, Stibbard S, Premsukh A,
Entwistle J, et al. (2011) Fusogenics: a recombinant immuno-
toxin-based screening platform to select internalizing tumor-
specific antibody fragments. J. Biomol. Screen. 16(1), 90-100.
49. Shaaltiel Y, Bartfeld D, Hashmueli S, Baum G, Brill-Almon E,
Galili G, et al. (2007) Production of glucocerebrosidase with
terminal mannose glycans for enzyme replacement therapy of
Gaucher's disease using a plant cell system. Plant Biotechnol.
J. 5(5), 579-590.
50. Aviezer D, Brill-Almon E, Shaaltiel Y, Hashmueli S, Bartfeld
D, Mizrachi S, et al. (2009) A plant-derived recombinant
human glucocerebrosidase enzyme-a preclinical and phase I
investigation. PLoS ONE 4(3), e4792.
51. Prince WS, McCormick LM, Wendt DJ, Fitzpatrick PA,
Schwartz KL, Aguilera AI, et al. (2004) Lipoprotein receptor
binding, cellular uptake, and lysosomal delivery of fusions
between the receptor-associated protein (RAP) and alpha-L-
iduronidase or acid alpha-glucosidase. J. Biol. Chem. 279(33),
35037-35046.
52. LeBowitz JH, Grubb JH, Maga JA, Schmiel DH, Vogler C, Sly
WS. (2004) Glycosylation-independent targeting enhances
enzyme delivery to lysosomes and decreases storage in muco-
polysaccharidosis type VII mice. Proc. Natl. Acad. Sci. USA
101(9), 3083-3088.
53. Orii KO, Grubb JH, Vogler C, Levy B, Tan Y, Markova K, et al.
(2005) Defining the pathway for Tat-mediated delivery of beta-
glucuronidase in cultured cells and MPS VII mice. Mol. Ther.
12(2), 345-352.
54. Lee KO, Luu N, Kaneski CR, Schiffmann R, Brady RO,
Murray GJ. (2005) Improved intracellular delivery of gluco-
cerebrosidase mediated by the HIV-1 TAT protein transduction
domain. Biochem. Biophys. Res. Commun. 337(2), 701-707.
55. Rapoport M, Salman L, Sabag O, Patel MS, Lorberboum-
Galski H. (2011) Successful TAT-mediated enzyme replace-
ment therapy in a mouse model of mitochondrial E3 deficiency.
J. Mol. Med. 89(2), 161-170.
56. Zhang F, Xing J, Liou AK-F, Wang S, Gan Y, Luo Y, et al.
(2010) Enhanced Delivery of Erythropoietin Across the Blood-
Brain Barrier for Neuroprotection against Ischemic Neuronal
Injury. Transl. Stroke Res. 1(2), 113-121.
57. Mie M, Takahashi F, Funabashi H, Yanagida Y, Aizawa M,
Kobatake E. (2003) Intracellular delivery of antibodies using
TAT fusion protein A. Biochem. Biophys. Res. Commun.
310(3), 730-734.
58. Frankel AD, Pabo CO. (1988) Cellular uptake of the tat protein
from human immunodeficiency virus. Cell 55(6), 1189-1193.
for murine hypophosphatasia. Bone 49(2),
250-256.
44. Kasugai S, Fujisawa R, Waki Y, Miyamoto K, Ohya K. (2000)
Selective drug delivery system to bone: small peptide (Asp)6
conjugation. J. Bone Miner. Res. 15(5), 936-943.
45. Takahashi-Nishioka T, Yokogawa K, Tomatsu S, Nomura M,
Kobayashi S, Miyamoto K-I. (2008) Targeted drug delivery to
Search WWH ::
Custom Search